Earnings Analysis of Golar LNG Limited(NASDAQ:GLNG) and Heron Therapeutics, Inc. (NASDAQ:HRTX)

0
5

Golar LNG Limited (GLNG) will report its next earnings on Feb 04 BMO. The company reported the earnings of $-0.45/Share in the last quarter where the estimated EPS by analysts was $-0.11/share. The difference between the expected and actual EPS was $-0.34/share, which represents an Earnings surprise of -309.1%.

Many analysts are providing their Estimated Earnings analysis for Golar LNG Limited and for the current quarter 16 analysts have projected that the stock could give an Average Earnings estimate of $0.13/share. These analysts have also projected a Low Estimate of $-0.57/share and a High Estimate of $0.53/share.

In case of Revenue Estimates, 15 analysts have provided their consensus Average Revenue Estimates for Golar LNG Limited as 134.05 Million. According to these analysts, the Low Revenue Estimate for Golar LNG Limited is 106.26 Million and the High Revenue Estimate is 155.2 Million. The company had Year Ago Sales of 57.59 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for GLNG to be 245.5%. They are projecting Next Quarter growth of 138.1%. For the next 5 years, Golar LNG Limited is expecting Growth of 126.99% per annum, whereas in the past 5 years the growth was 32.65% per annum.

Some buy side analysts are also providing their Analysis on Golar LNG Limited, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Golar LNG Limited might touch $46 high while the Average Price Target and Low price Target is $37.06 and $32 respectively.

Golar LNG Limited closed its last trading session at $24.38 with the loss of -2.26%. The Market Capitalization of the company stands at 2.35 Billion. The Company has 52-week high of $35.54 and 52-week low of $20.49. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 3.56% where SMA50 and SMA200 are -5.25% and -13.19% respectively. The Company Touched its 52-Week High on 05/22/18 and 52-Week Low on 12/20/18.

The Relative Volume of the company is 0.71 and Average Volume (3 months) is 1.55 million. The company’s P/E (price to earnings) ratio is 28.3 and Forward P/E ratio of 63.21.

The company shows its Return on Assets (ROA) value of 1.7%. The Return on Equity (ROE) value stands at 4.8%. While it’s Return on Investment (ROI) value is -2.1%.

While looking at the Stock’s Performance, Golar LNG Limited currently shows a Weekly Performance of 6.1%, where Monthly Performance is -5.7%, Quarterly performance is -11.81%, 6 Months performance is -17.69% and yearly performance percentage is -18.61%. Year to Date performance value (YTD perf) value is 9.51%. The Stock currently has a Weekly Volatility of 3.03% and Monthly Volatility of 4.60%.

Heron Therapeutics, Inc. (HRTX) will report its next earnings on Feb 06 AMC. The company reported the earnings of $-0.49/Share in the last quarter where the estimated EPS by analysts was $-0.45/share. The difference between the expected and actual EPS was $-0.04/share, which represents an Earnings surprise of -8.9%.

Many analysts are providing their Estimated Earnings analysis for Heron Therapeutics, Inc. and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $-0.49/share. These analysts have also projected a Low Estimate of $-0.6/share and a High Estimate of $-0.34/share.

In case of Revenue Estimates, 9 analysts have provided their consensus Average Revenue Estimates for Heron Therapeutics, Inc. as 23.72 Million. According to these analysts, the Low Revenue Estimate for Heron Therapeutics, Inc. is 22.2 Million and the High Revenue Estimate is 28 Million. The company had Year Ago Sales of 10.05 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for HRTX to be 53.6%. They are projecting Next Quarter growth of 54.32%. For the next 5 years, Heron Therapeutics, Inc. is expecting Growth of 63.5% per annum, whereas in the past 5 years the growth was -154.39% per annum.

Some buy side analysts are also providing their Analysis on Heron Therapeutics, Inc. , where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Heron Therapeutics, Inc. might touch $76 high while the Average Price Target and Low price Target is $53.45 and $42 respectively.

Heron Therapeutics, Inc. closed its last trading session at $25.34 with the gain of 2.6%. The Market Capitalization of the company stands at 2.02 Billion. The Company has 52-week high of $42.90 and 52-week low of $18.65. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.35% where SMA50 and SMA200 are -2.08% and -18.55% respectively. The Company Touched its 52-Week High on 06/25/18 and 52-Week Low on 02/09/18.

The Relative Volume of the company is 1.11 and Average Volume (3 months) is 993.61 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -54.8%. The Return on Equity (ROE) value stands at -72.2%. While it’s Return on Investment (ROI) value is -121.8%.

While looking at the Stock’s Performance, Heron Therapeutics, Inc. currently shows a Weekly Performance of -0.34%, where Monthly Performance is -3.45%, Quarterly performance is -15.03%, 6 Months performance is -32.64% and yearly performance percentage is 38.3%. Year to Date performance value (YTD perf) value is 0.23%. The Stock currently has a Weekly Volatility of 6.84% and Monthly Volatility of 6.78%.

SHARE